Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 4/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | CASP1 | P29466 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 4/20 | 0.51 |
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | CASP3 | P42574 | 1/20 | 0.51 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27790139 | 0.89 | ALOX15 (0.53) | CES1ALOX15TSHRCASP1RAB9A | |
| SCHEMBL16703005 | 0.88 | CES1 (0.54) | CES1ALOX15TSHRCASP1RAB9A | |
| SCHEMBL4808388 | 0.85 | ALOX15 (0.50) | CES1ALOX15TSHRCASP1RAB9A | |
| SCHEMBL28531830 | 0.85 | RAB9A (0.60) | CES1ALOX15TSHRCASP1RAB9A | |
| SCHEMBL370029 | 0.84 | ALDH1A1 (0.59) | CES1RAB9ANPC1ALDH1A1HPGD | |
| SCHEMBL16702745 | 0.84 | HDAC1 (0.46) | CES1ALOX15TSHRCASP1RAB9A | |
| SCHEMBL22437008 | 0.84 | MAP4K4 (0.54) | CES1RAB9ANPC1ALDH1A1HPGD | |
| SCHEMBL31301477 | 0.84 | RAB9A (0.51) | CES1ALOX15TSHRCASP1RAB9A | |
| SCHEMBL23041964 | 0.82 | NPC1 (0.56) | CES1TSHRRAB9ANPC1ALDH1A1 | |
| SCHEMBL31341107 | 0.82 | NR4A1 (0.61) | CES1GAAFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 139 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3710428-B1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2026-03-25 | — | — | EP | disclosed |
| EP-3623372-B1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | VALO HEALTH INC (US) | 2026-02-04 | — | — | EP | disclosed |
| EP-4676929-A1 | PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 | Dark Blue Therapeutics Ltd (GB) | 2026-01-14 | — | — | EP | disclosed |
| US-12509424-B2 | Compound and composition as PDGF receptor kinase inhibitor | NIPPON SHINYAKU CO., LTD. (JP) | 2025-12-30 | — | — | US | disclosed |
| EP-4638447-A1 | IMIDAZO[1,2-A]PYRIDINE AND IMIDAZO[1,2-A]PYRAZINE DERIVATIVES AS MLLT1 AND MLLT3 INHIBITORS | Dark Blue Therapeutics Ltd (GB) | 2025-10-29 | — | — | EP | disclosed |
| EP-4568666-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | Alexion Pharmaceuticals, Inc. (US) | 2025-06-18 | — | — | EP | disclosed |
| US-20250145594-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2025-05-08 | — | — | US | disclosed |
| CN-119768164-A | Pharmaceutical compounds for treating complement-mediated disorders | 阿雷克森制药公司 | 2025-04-04 | — | — | CN | disclosed |
| EP-4516778-A1 | COMPOUND SERVING AS DDR1 KINASE INHIBITOR, AND MEDICINE | Nippon Shinyaku Co., Ltd. (JP) | 2025-03-05 | — | — | EP | disclosed |
| EP-4516777-A2 | COMPOUND AND COMPOSITION AS PDGF RECEPTOR KINASE INHIBITOR | Nippon Shinyaku Co., Ltd. (JP) | 2025-03-05 | — | — | EP | disclosed |
| EP-1311505-A2 | QUINUCLIDINE-SUBSTITUTED HETEROARYL MOIETIES FOR TREATMENT OF DISEASE ( NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS ) | PHARMACIA & UPJOHN COMPANY (US) | 2003-05-21 | — | — | EP | disclosed |
| WO-2003040147-A1 | AZABICYCLIC-SUBSTITUTED-HETEROARYL COMPOUNDS FOR THE TREATMENT OF DISEASE__________________________________________________________________________________________________________________________ | PHARMACIA & UPJOHN COMPANY (US) | 2003-05-15 | — | — | WO | disclosed |
| US-6500840-B2 | CENTRAL NERVOUS SYSTEM DISORDERS | PHARMACIA & UPJOHN COMPANY | 2002-12-31 | — | — | US | disclosed |
| US-6492385-B2 | CENTRAL NERVOUS SYSTEM DISORDERS | PHARMACIA & UPJOHN COMPANY | 2002-12-10 | — | — | US | disclosed |
| US-20020091135-A1 | Quinuclidine-substituted heteroaryl moieties for treatment of disease | PHARMACIA & UPJOHN COMPANY GLOBAL INTELLECTUAL PROPERTY | 2002-07-11 | — | — | US | disclosed |
| US-20020042428-A1 | Quinuclidine-substituted heteroaryl moieties for treatment of disease | PHARMACIA & UPJOHN COMPANY | 2002-04-11 | — | — | US | disclosed |
| US-20020042429-A1 | Quinuclidine-substituted heteroaryl moieties for treatment of disease | PHARMACIA & UPJOHN COMPANY | 2002-04-11 | — | — | US | disclosed |
| WO-2002015662-A2 | QUINUCLIDINE-SUBSTITUTED HETEROARYL MOIETIES FOR TREATMENT OF DISEASE (NICOTINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | PHARMACIA & UPJOHN COMPANY (US) | 2002-02-28 | — | — | WO | disclosed |
| WO-2002016355-A2 | QUINUCLIDINE-SUBSTITUTED HETEROARYL MOIETIES FOR TREATMENT OF DISEASE (NICOTINIC) ACETYLCHOLINE RECEPTOR LIGANDS | PHARMACIA & UPJOHN COMPANY (US) | 2002-02-28 | — | — | WO | disclosed |
| WO-2002017358-A2 | QUINUCLIDINE-SUBSTITUTED HETEROARYL MOIETIES FOR TREATMENT OF DISEASE (NICOTINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS) | PHARMACIA & UPJOHN COMPANY (US) | 2002-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12509424-B2 | Compound and composition as PDGF receptor kinase inhibitor | PDGFRA, PDGFRB, PDGFA | CES1 2200/4885ALOX15 1636/4885TSHR 2443/4885 |
| US-20250145594-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | CES1 1563/4885ALOX15 659/4885TSHR 3690/4885 |
| US-20020042428-A1 | Quinuclidine-substituted heteroaryl moieties for treatment of disease | NQO2, GBA1, UGT1A1 | CES1 238/4885ALOX15 1880/4885TSHR 2341/4885 |
| US-20020042429-A1 | Quinuclidine-substituted heteroaryl moieties for treatment of disease | PARK7, CYP3A7, UGT2B7 | CES1 408/4885ALOX15 1766/4885TSHR 2402/4885 |
| US-20020091135-A1 | Quinuclidine-substituted heteroaryl moieties for treatment of disease | NQO2, GBA1, UGT1A1 | CES1 238/4885ALOX15 1880/4885TSHR 2341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.